The layoffs come as the drugmaker works to revise its research and development strategy under its new R&D chief Hal Barron.
Most of the job cuts will affect chemists at its facility in Upper Providence, Pa., as well as some administrative roles.
A few R&D jobs at its facility in Stevenage, U.K., also will be eliminated.
Read the full report here.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
